Home › NDC Lookup › RxCUI directory › RxCUI 2729307

14 ML amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Fas... — RxCUI 2729307

RxNorm drug concept · Semantic branded drug
RxCUI 2729307 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2729307
Official name14 ML amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asRybrevant Faspro 2240 MG / 28000 UNT per 14 ML Injection; Rybrevant Faspro 2240 MG / 28000 UNT in 14 ML Injection; Rybrevant Faspro (amivantamab-lpuj 2240 MG / hyaluronidase-lpuj 28000 UNT) per 14 ML Injection
FDA products mapped4
Package NDCs mapped4
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Amivantamab-vmjw Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Rybrevant only works against lung cancer cells that have a specific change — called a mutation — in the EGFR gene. There are different types of EGFR mutations, and which one you ha...
  • Why does my tumor have to be tested before I can get Rybrevant?
  • Infusion-related reactions — things like flushing, chills, fever, or shortness of breath — are very common during Rybrevant infusions, especially on the very first day. The premedi...
  • Why did my nurse give me so many medications before my first Rybrevant infusion?
📖 Read our full Amivantamab-vmjw Injection guide →

🕸️ Concept Web — How 14 ML amivantamab-lpuj 160 MG/ML / hyaluronidase... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 14 ML amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML Injection [Rybrevant Faspro] RxCUI 2729307

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Amivantamab 2549199
    • Hyaluronidase 5464
    • Amivantamab / hyaluronidase 2729292
    • Amivantamab-lpuj 2729288
    • Hyaluronidase-lpuj 2729290
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Rybrevant Faspro 2729299
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Amivantamab / hyaluronidase Injection 2729294
    • Amivantamab-lpuj / hyaluronidase-lpuj Injection 2729296
    • Amivantamab / hyaluronidase Injectable Product 2729293
    • Amivantamab-lpuj / hyaluronidase-lpuj Injectable Product 2729295
    • Amivantamab / hyaluronidase Injection [Rybrevant Faspro] 2729302
    • Amivantamab-lpuj / hyaluronidase-lpuj Injection [Rybrevant Faspro] 2729303
    • Rybrevant Faspro Injectable Product 2729301
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 14 ML amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML Injection SCD · 2729306
  • Amivantamab-lpuj 160 MG/ML SCDC · 2729289
  • Hyaluronidase-lpuj 2000 UNT/ML SCDC · 2729291
  • Amivantamab / hyaluronidase Injection SCDF · 2729294
  • Amivantamab-lpuj / hyaluronidase-lpuj Injection SCDFP · 2729296
  • Amivantamab / hyaluronidase Injectable Product SCDG · 2729293
  • Amivantamab-lpuj / hyaluronidase-lpuj Injectable Product SCDGP · 2729295

Brand-Name Concepts

  • Amivantamab-lpuj 160 MG/ML / hyaluronidase-lpuj 2000 UNT/ML [Rybrevant Faspro] SBDC · 2729300
  • Amivantamab / hyaluronidase Injection [Rybrevant Faspro] SBDF · 2729302
  • Amivantamab-lpuj / hyaluronidase-lpuj Injection [Rybrevant Faspro] SBDFP · 2729303
  • Rybrevant Faspro Injectable Product SBDG · 2729301
  • Rybrevant Faspro BN · 2729299

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2729307 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
57894-0510-01 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-510-01) / 10 mL in 1... Rybrevant Faspro Janssen Biotech, Inc. 2025-12-19
57894-0514-01 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-514-01) / 14 mL in 1... Rybrevant Faspro Janssen Biotech, Inc. 2025-12-19
57894-0515-01 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-515-01) / 15 mL in 1... Rybrevant Faspro Janssen Biotech, Inc. 2026-02-13
57894-0522-01 1 VIAL, SINGLE-DOSE in 1 CARTON (57894-522-01) / 22 mL in 1... Rybrevant Faspro Janssen Biotech, Inc. 2026-02-13
Observed labelers: Janssen Biotech, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9062 Inj amivantamab 5mg hyaluron 4 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.